MARAVAI LIFESCIENCES HOLDINGS INC

NASDAQ: MRVI (Maravai LifeSciences Holdings,)

Last update: 07 Nov, 3:16PM

7.84

-0.19 (-2.37%)

Previous Close 8.03
Open 8.09
Volume 2,026,948
Avg. Volume (3M) 1,931,964
Market Cap 1,977,538,048
Price / Earnings (Forward) 370.37
Price / Sales 2.63
Price / Book 2.21
52 Weeks Range
4.52 (-42%) — 11.56 (47%)
Earnings Date 7 Nov 2024
Profit Margin -81.13%
Operating Margin (TTM) -23.09%
Diluted EPS (TTM) -1.67
Quarterly Revenue Growth (YOY) -2.50%
Total Debt/Equity (MRQ) 100.03%
Current Ratio (MRQ) 10.74
Operating Cash Flow (TTM) 29.89 M
Levered Free Cash Flow (TTM) 8.86 M
Return on Assets (TTM) -1.61%
Return on Equity (TTM) -42.93%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Maravai LifeSciences Holdings, Bearish Bullish

AIStockmoo Score

-0.4
Analyst Consensus -0.5
Insider Activity 0.0
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators -2.0
Average -0.40

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MRVI 2 B - - 2.21
VKTX 5 B - - 5.75
BBIO 5 B - - -
CRNX 5 B - - 6.70
KRYS 5 B - 87.77 5.77
DYN 3 B - - 4.23

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 1.45%
% Held by Institutions 102.69%
52 Weeks Range
4.52 (-42%) — 11.56 (47%)
Price Target Range
4.25 (-45%) — 13.00 (65%)
High 13.00 (RBC Capital, 65.82%) Buy
Median 9.00 (14.80%)
Low 4.25 (Goldman Sachs, -45.79%) Sell
Average 8.75 (11.61%)
Total 2 Buy, 1 Sell
Avg. Price @ Call 5.08
Firm Date Target Price Call Price @ Call
Goldman Sachs 05 Dec 2024 4.25 (-45.79%) Sell 5.09
08 Oct 2024 7.00 (-10.71%) Hold 7.68
Baird 08 Nov 2024 9.00 (14.80%) Buy 5.08
RBC Capital 08 Nov 2024 13.00 (65.82%) Buy 5.08
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
ECKERT R ANDREW 5.58 - 134,409 750,002
LUCIER GREGORY T 5.43 5.43 0 0
Aggregate Net Quantity 134,409
Aggregate Net Value ($) 750,002
Aggregate Avg. Buy ($) 5.51
Aggregate Avg. Sell ($) 5.43
Name Holder Date Type Quantity Price Value ($)
ECKERT R ANDREW Director 16 Dec 2024 Acquired (+) 134,409 5.58 750,002
LUCIER GREGORY T Director 09 Dec 2024 Disposed (-) 20,645 5.43 112,102
LUCIER GREGORY T Director 09 Dec 2024 Acquired (+) 20,645 5.43 112,102

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria